Latest / WTR Small-Cap Spotlight
GenSight Biologics' Novel Gene Therapy Approach to Reversing Blindness from Genetic Eye Disorders
Send us Fan Mail
On the latest WTR Small-Cap Spotlight podcast episode, we welcomed Jan Eryk Umiastowski, CFO of GenSight Biologics (Euronext Paris: SIGHT), a late clinical-stage biopharma company based in Paris, France, primarily focused on developing and commercializing novel disease-modifying gene therapies aimed at reversing vision loss from severe neurodegenerative retinal diseases. He discusses GenSight's development pipeline, what's unique about the company's approach to gene therapy and upcoming target milestones.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.